Ketamine or ECT? What Have We Learned From the KetECT and ELEKT-D Trials?
Joakim Ekstrand1, Akihiro Takamiya2,3, Axel Nordenskjold4
1Department of Clinical Sciences, Division of Adult Psychiatry Faculty of Medicine, Lund University, Lund, Sweden.
The International Journal of Neuropsychopharmacology
|December 19, 2023
Summary
Ketamine and electroconvulsive therapy (ECT) show varied effectiveness for major depressive disorder. Differences in ECT outcomes between trials highlight the need for personalized treatment approaches for depression.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Trials
Background:
- Major depressive disorder (MDD) is a leading cause of disability worldwide.
- Electroconvulsive therapy (ECT) is a well-established treatment for severe MDD.
- Ketamine is an emerging rapid-acting treatment for depression.
Purpose of the Study:
- To compare the effectiveness of ketamine and ECT for major depressive disorder.
- To analyze discrepancies in ECT outcomes between two recent clinical trials (KetECT and ELEKT-D).
- To explore factors contributing to outcome variations and inform personalized treatment strategies.
Main Methods:
- Comparative analysis of two clinical trials: KetECT and ELEKT-D.
- Examination of patient characteristics, treatment protocols, and study designs.
- Assessment of remission rates for ketamine and ECT in both trials.
Main Results:
- Significant differences in ECT remission rates were observed: 63% in KetECT versus 22% in ELEKT-D.
- Ketamine remission rates were 46% (KetECT) and 38% (ELEKT-D).
- Discrepancies suggest heterogeneity in treatment response and study methodologies.
Conclusions:
- The effectiveness of ECT for major depressive disorder can vary significantly based on trial parameters.
- Patient characteristics and treatment protocols are crucial for optimizing ketamine and ECT efficacy.
- These findings emphasize the need for personalized treatment selection in managing depression.
